Charter Research - Lady Lake

The trials here

What the 22 trials at this site are about, from their registry records.

Conditions

• Obesity10 trials
• Alzheimer disease9 trials
• Type 2 diabetes5 trials
• Osteoarthritis2 trials
• Frontotemporal dementia1 trial

Phase

• Phase 215 trials
• Phase 37 trials

Status

• Completed7 trials
• Active, not recruiting6 trials
• Recruiting6 trials
• Not yet recruiting1 trial
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company19 trials
• Acumen Pharmaceuticals1 trial
• Bristol-Myers Squibb1 trial
• Celgene1 trial

Running trials

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Eli Lilly and Company· Source

  Contact: Jeffrey Norton (principal investigator)

• Recruiting

  A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

  NCT07641517· Phase 2· Eli Lilly and Company· Source

  Contact: Stephen Miller (principal investigator)

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Eli Lilly and Company· Source

  Contact: Jeffrey Norton (principal investigator)

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Bristol-Myers Squibb· Source

  Contact: Jeffrey Norton, Site 0184

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

  NCT06808984· Phase 2· Celgene· Source

  Contact: Jeffrey Norton, Site 0039

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

  NCT07035093· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

  NCT06335173· Phase 2· Acumen Pharmaceuticals· Source

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Eli Lilly and Company· Source

  Contact: Jeffrey Norton (principal investigator)

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

  NCT05986292· Phase 2· Eli Lilly and Company· Source

  Contact: Stephen Miller (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Alzheimer disease2 recruiting
• Osteoarthritis2 recruiting
• Type 2 diabetes2 recruiting

Closed trials

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Phase 2· Eli Lilly and Company· Source

• Withdrawn

  A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06901349· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Eli Lilly and Company· Source

• Completed

  Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

  NCT06568042· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06124807· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

  NCT05063539· Phase 2· Eli Lilly and Company· Source